JP7798300B2 - 脂肪肝および非アルコール性脂肪肝炎の治療薬 - Google Patents

脂肪肝および非アルコール性脂肪肝炎の治療薬

Info

Publication number
JP7798300B2
JP7798300B2 JP2023550943A JP2023550943A JP7798300B2 JP 7798300 B2 JP7798300 B2 JP 7798300B2 JP 2023550943 A JP2023550943 A JP 2023550943A JP 2023550943 A JP2023550943 A JP 2023550943A JP 7798300 B2 JP7798300 B2 JP 7798300B2
Authority
JP
Japan
Prior art keywords
fatty liver
amino acid
acid sequence
pharmaceutical composition
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023550943A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023053384A5 (https=
JPWO2023053384A1 (https=
Inventor
克人 玉井
敬史 新保
崇二 寺井
淳紀 土屋
尊彦 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niigata University NUC
StemRIM Inc
University of Osaka NUC
Original Assignee
Niigata University NUC
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niigata University NUC, Osaka University NUC, StemRIM Inc filed Critical Niigata University NUC
Publication of JPWO2023053384A1 publication Critical patent/JPWO2023053384A1/ja
Publication of JPWO2023053384A5 publication Critical patent/JPWO2023053384A5/ja
Application granted granted Critical
Publication of JP7798300B2 publication Critical patent/JP7798300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023550943A 2021-09-30 2021-09-30 脂肪肝および非アルコール性脂肪肝炎の治療薬 Active JP7798300B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2021/036238 WO2023053384A1 (ja) 2021-09-30 2021-09-30 脂肪肝および非アルコール性脂肪肝炎の治療薬

Publications (3)

Publication Number Publication Date
JPWO2023053384A1 JPWO2023053384A1 (https=) 2023-04-06
JPWO2023053384A5 JPWO2023053384A5 (https=) 2024-10-07
JP7798300B2 true JP7798300B2 (ja) 2026-01-14

Family

ID=85781770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023550943A Active JP7798300B2 (ja) 2021-09-30 2021-09-30 脂肪肝および非アルコール性脂肪肝炎の治療薬

Country Status (9)

Country Link
US (1) US20240299496A1 (https=)
EP (1) EP4410302A4 (https=)
JP (1) JP7798300B2 (https=)
KR (1) KR20240070640A (https=)
CN (1) CN118317780A (https=)
AU (1) AU2021466375A1 (https=)
CA (1) CA3233234A1 (https=)
MX (1) MX2024003974A (https=)
WO (2) WO2023053384A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018186480A1 (ja) 2017-04-07 2018-10-11 株式会社ステムリム 線維性疾患の治療薬
US20200282017A1 (en) 2019-03-06 2020-09-10 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
JP2021508491A (ja) 2017-12-18 2021-03-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3358011T (pt) 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018186480A1 (ja) 2017-04-07 2018-10-11 株式会社ステムリム 線維性疾患の治療薬
JP2021508491A (ja) 2017-12-18 2021-03-11 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 高移動度グループボックス−１（ＨＭＧＢ１）ｉＲＮＡ組成物及びその使用方法
US20200282017A1 (en) 2019-03-06 2020-09-10 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [Online]，Retrieved from STN，US: American Chemical Society [retrieved on 2021.，Registry No. 1606186-88-2， (Entered STN 2014.05.18)
NOJIRI Shunsuke et al.，Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice，Inflammation and Regeneration，2021年，Vol.41，Article No. 28，ISSN 1880-9693
S-005151の慢性肝疾患患者を対象とした第２相試験，国立保健医療科学院 [online]，2021年01月07日，[retrieve on 2021.11.05], Retrieved from the Internet: <URL: https://rctportal.niph.go.jp/s/detail/um?trial_id=jRCT2031200232>
医薬品の一般的名称について，薬生薬審発第1016001号，[retrieved on 2021.11.09], Retrieved from the Internet: <URL: https://www.mhlw.go.jp/web/t_doc?dataId=00tc4538&dataType=1&pageNo=1> and <URL: https://www.mhlw.go.jp/web/t_img?img=3727191>
土屋淳紀，HMGB1の部分ペプチドを用いた慢性肝疾患に対するセルフリー治療の開発，肝臓，2021年04月20日，Vol.62, Suppl.1，p.A69, Abstract No.PD2-7
日本初の人工ペプチド「レダセムチド（S-005151）」を用いた慢性肝疾患に対する線維化改善、再生促進を目指，新潟大学［online］，2020年11月12日，[retrieved on 2021.11.05］, Retrieved from the Internet: <URL：https://www.niigata-u.ac.jp/wp-content/uploads/2020/11/201112topi.pdf>

Also Published As

Publication number Publication date
US20240299496A1 (en) 2024-09-12
EP4410302A1 (en) 2024-08-07
EP4410302A4 (en) 2025-07-23
AU2021466375A1 (en) 2024-04-11
KR20240070640A (ko) 2024-05-21
CA3233234A1 (en) 2023-04-06
WO2023054666A1 (ja) 2023-04-06
CN118317780A (zh) 2024-07-09
JPWO2023053384A1 (https=) 2023-04-06
WO2023053384A1 (ja) 2023-04-06
MX2024003974A (es) 2024-07-09

Similar Documents

Publication Publication Date Title
JP6936366B2 (ja) 胆汁酸に関係した障害の治療方法
JP6634402B2 (ja) 代謝障害及び疾患の治療のための組成物、使用及び方法
ES2523463T3 (es) Composiciones para inhibir la angiogénesis
EP3603660B1 (en) Long-acting mutant human fibroblast growth factor 21 for treating non-alcoholic steatohepatitis
Xu et al. Macrophage migration inhibitory factor (MIF) knockout preserves cardiac homeostasis through alleviating Akt-mediated myocardial autophagy suppression in high-fat diet-induced obesity
EA011583B1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
BR112020013644A2 (pt) produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit.
Fathallah et al. Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics
JP2022516509A (ja) 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）を治療するための組成物および方法
CN112274523A (zh) 一种治疗脂肪肝的药物和治疗方法
Chen et al. Thymosinβ4 alleviates cholestatic liver fibrosis in mice through downregulating PDGF/PDGFR and TGFβ/Smad pathways
JP6913402B2 (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）の治療と予防に適した配合剤
US20170368119A1 (en) Methods and compositions for treating c-met associated cancers
KR20250166323A (ko) 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
JP7798300B2 (ja) 脂肪肝および非アルコール性脂肪肝炎の治療薬
CN118161613A (zh) 抑制肝细胞中Fmrp蛋白的表达量的试剂在制备治疗非酒精性脂肪肝病的药物中的应用
EP3344279B1 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
Chiang et al. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis
CN114288300B (zh) 常山酮在治疗和预防脂肪肝、肥胖的药物中的应用
HK40107111A (en) Drug for treating fatty liver and non-alcoholic steatohepatitis
JP7102390B2 (ja) Ａｐｏａ１の投与のための組成物及び投薬形態
US20230201311A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis (nash)
CN116019914B (zh) Gpr180抑制剂在制备改善糖或脂代谢药物中的用途
CN116549632B (zh) 抗Lingo-1抗体Opicinumab的新用途及针对新用途的药物
HK40083624A (en) Compositions and methods for treating non-alcoholic steatohepatitis (nash)

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20240327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240405

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240927

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251217

R150 Certificate of patent or registration of utility model

Ref document number: 7798300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150